Zydus Cadila has received final approval from the USFDA to market Imatinib Mesylate Tablets, 100 mg and 400 mg. (US RLD: Gleevec® Tablets)
This medication is used to treat certain types of leukemia (blood cancer), bone marrow disorders, skin cancer and tumors of the stomach and digestive system. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, in Ahmedabad.
The group now has 285 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.349.95 as compared to the previous close of Rs. 312.5. The total number of shares traded during the day was 1418348 in over 40362 trades.
The stock hit an intraday high of Rs. 366.55 and intraday low of 331.35. The net turnover during the day was Rs. 496537085.